[
    [
        {
            "time": "2021-03-30",
            "original_text": "凯美纳销售继续放量——贝达药业调研纪要20210330",
            "features": {
                "keywords": [
                    "凯美纳",
                    "销售放量",
                    "贝达药业"
                ],
                "sentiment_score": 0.9,
                "policy_related": "false",
                "investment_strategy": "true",
                "sector_focus": [
                    "医药"
                ],
                "causal_factor": "true",
                "causal_impact": "positive",
                "affected_by_time_series": "true",
                "ts_effect_direction": "positive"
            },
            "scores": {
                "News_content": "凯美纳销售继续放量——贝达药业调研纪要20210330",
                "Correlation": 9,
                "Sentiment": 8,
                "Importance": 7,
                "Impact": 7,
                "Duration": 6,
                "Entity_Density": 8,
                "Market_Scope": 4,
                "Time_Proximity": 5,
                "Headline_Structure": 7,
                "Source_Recency": 6
            }
        },
        {
            "time": "2021-03-30",
            "original_text": "贝达药业：埃克替尼术后辅助治疗适应症上市申请有望上半年获批",
            "features": {
                "keywords": [
                    "贝达药业",
                    "埃克替尼",
                    "术后辅助治疗",
                    "适应症获批"
                ],
                "sentiment_score": 0.85,
                "policy_related": "false",
                "investment_strategy": "true",
                "sector_focus": [
                    "医药"
                ],
                "causal_factor": "true",
                "causal_impact": "positive",
                "affected_by_time_series": "true",
                "ts_effect_direction": "positive"
            },
            "scores": {
                "News_content": "贝达药业：埃克替尼术后辅助治疗适应症上市申请有望上半年获批",
                "Correlation": 10,
                "Sentiment": 9,
                "Importance": 9,
                "Impact": 8,
                "Duration": 7,
                "Entity_Density": 9,
                "Market_Scope": 3,
                "Time_Proximity": 6,
                "Headline_Structure": 8,
                "Source_Recency": 7
            }
        },
        {
            "time": "2020-年报",
            "original_text": "东方财富证券-贝达药业2020年报点评：凯美纳累计销售超90亿，创新产品接踵而至【公司研究】",
            "features": {
                "keywords": [
                    "贝达药业",
                    "凯美纳",
                    "累计销售",
                    "创新产品"
                ],
                "sentiment_score": 0.9,
                "policy_related": "false",
                "investment_strategy": "true",
                "sector_focus": [
                    "医药"
                ],
                "causal_factor": "true",
                "causal_impact": "positive",
                "affected_by_time_series": "true",
                "ts_effect_direction": "positive"
            },
            "scores": {
                "News_content": "东方财富证券-贝达药业2020年报点评：凯美纳累计销售超90亿，创新产品接踵而至【公司研究】",
                "Correlation": 10,
                "Sentiment": 9,
                "Importance": 9,
                "Impact": 8,
                "Duration": 8,
                "Entity_Density": 10,
                "Market_Scope": 4,
                "Time_Proximity": 6,
                "Headline_Structure": 8,
                "Source_Recency": 7
            }
        },
        {
            "time": "去年一季报",
            "original_text": "去年一季报营收为0未盈利药企天广实主动撤回科创板IPO IPO融资异常",
            "features": {
                "keywords": [
                    "天广实",
                    "科创板IPO",
                    "撤回",
                    "融资异常"
                ],
                "sentiment_score": -0.7,
                "policy_related": "false",
                "investment_strategy": "true",
                "sector_focus": [
                    "医药"
                ],
                "causal_factor": "true",
                "causal_impact": "negative",
                "affected_by_time_series": "true",
                "ts_effect_direction": "negative"
            },
            "scores": {
                "News_content": "去年一季报营收为0未盈利药企天广实主动撤回科创板IPO IPO融资异常",
                "Correlation": 6,
                "Sentiment": 3,
                "Importance": 7,
                "Impact": 6,
                "Duration": 5,
                "Entity_Density": 7,
                "Market_Scope": 5,
                "Time_Proximity": 7,
                "Headline_Structure": 8,
                "Source_Recency": 8
            }
        },
        {
            "time": "近期",
            "original_text": "复宏汉霖11亿元与润新生物达成独家许可交易；先声药业引进PI3K/mTOR抑制剂；来凯医药启动卵巢癌1类新药全球注册临床研究",
            "features": {
                "keywords": [
                    "复宏汉霖",
                    "润新生物",
                    "独家许可",
                    "先声药业",
                    "PI3K/mTOR抑制剂",
                    "来凯医药",
                    "卵巢癌新药"
                ],
                "sentiment_score": 0.8,
                "policy_related": "false",
                "investment_strategy": "true",
                "sector_focus": [
                    "医药"
                ],
                "causal_factor": "true",
                "causal_impact": "positive",
                "affected_by_time_series": "true",
                "ts_effect_direction": "positive"
            },
            "scores": {
                "News_content": "复宏汉霖11亿元与润新生物达成独家许可交易；先声药业引进PI3K/mTOR抑制剂；来凯医药启动卵巢癌1类新药全球注册临床研究",
                "Correlation": 5,
                "Sentiment": 7,
                "Importance": 7,
                "Impact": 6,
                "Duration": 6,
                "Entity_Density": 6,
                "Market_Scope": 8,
                "Time_Proximity": 7,
                "Headline_Structure": 7,
                "Source_Recency": 7
            }
        }
    ]
]